表观遗传药物在结直肠癌治疗中的研究进展

doi:10.3969/j.issn.1674-490X.2020.04.003

摘要/Abstract

摘要： 结直肠癌(colorectal cancer,CRC)是常见的消化道恶性肿瘤之一,其患病率和病死率均呈逐年上升趋势,严重威胁人类健康。结直肠癌的表型演变经历了腺瘤-腺癌两个阶段,其发生、发展是一系列遗传学和表观遗传学事件积累的过程。有研究发现,表观遗传学改变在结直肠癌的启动和进展过程中发挥着更重要的作用。此外,由于表观遗传调控的异常改变通常发生于恶性肿瘤的早期阶段,因此可以作为早期诊断的分子标志物以提高诊断的准确性。近年来,表观遗传治疗除了在初治以及难治复发性骨髓增生异常综合征等恶性血液病患者的治疗中取得了显著的效果,在结直肠癌等恶性实体肿瘤的临床研究也在广泛开展中。

关键词: 结直肠癌, 表观遗传学, DNA甲基化, 组蛋白修饰, 非编码RNA

Abstract: Colorectal cancer(CRC)is one of the common malignant tumors of the digestive tract, and its morbidity and mortality are increasing year by year, which seriously threatens human health. The phenotypic evolution of colorectal cancer has gone through two stages(adenoma-adenocarcinoma), and its occurrence and development are the accumulation process of a series of genetic and epigenetic events. Studies have found that epigenetic changes play a more important role in the initiation and progression of colorectal cancer. In addition, because abnormal changes in epigenetic regulation usually occur in the early stages of malignant tumors, they can be used as molecular markers for early diagnosis to improve the accuracy of diagnosis. In recent years, epigenetic therapy has achieved remarkable effects in the treatment of patients with malignant hematological diseases such as primary and refractory relapsed myelodysplastic syndromes, and clinical research in malignant solid tumors such as colorectal cancer is also widely explored.

Key words: colorectal cancer, epigenetics, DNA methylation, histone modification, non-coding RNA

中图分类号:

朱波,刘经纬,豆建,李日恒. 表观遗传药物在结直肠癌治疗中的研究进展[J]. 医学研究与教育, 2020, 37(4): 13-19.

参考文献

[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
[2] ARNOLD M, SIERRA M S, LAVERSANNE M, et al. Global patterns and trends in colorectal cancer incidence and mortality[J]. Gut, 2017, 66(4): 683-691. DOI: 10.1136/gutjnl-2015-310912.
[3] JEON J, DU M M, SCHOEN R E, et al. Determining risk of colorectal cancer and starting age of screening based on lifestyle, environmental, and genetic factors[J]. Gastroenterology, 2018, 154(8): 2152-2164. DOI: 10.1053/j.gastro.2018.02.021.
[4] QIU T Z, CHEN W S, LI P, et al. Subsequent anti-VEGF therapy after first-line anti-EGFR therapy improved overall survival of patients with metastatic colorectal cancer[J]. Onco Targets Ther, 2018, 11: 465-471. DOI: 10.2147/ott.s149110.
[5] VIALE G,TRAPANT D,CURIGLIANO G. Mismatch repair deficiency as a predictive biomarker for immunotherapy efficacy[J]. Biomed Res Int, 2017, 2017: 1-7. DOI: 10.1155/2017/4719194.
[6] BARETTI M, AZAD N S. The role of epigenetic therapies in colorectal cancer[J]. Curr Probl Cancer, 2018, 42(6): 530-547. DOI: 10.1016/j.currproblcancer.2018.03.001.
[7] HENIKOFF S, GREALLY J M. Epigenetics, cellular memory and gene regulation[J]. Curr Biol, 2016, 26(14): R644-R648. DOI: 10.1016/j.cub.2016.06.011.
[8] ALLIS C D, JENUWEIN T. The molecular hallmarks of epigenetic control[J]. Nat Rev Genet, 2016, 17(8): 487-500. DOI: 10.1038/nrg.2016.59.
[9] SKVORTSOVA K, IOVINO N, BOGDANOVIC ' O. Functions and mechanisms of epigenetic inheritance in animals[J]. Nat Rev Mol Cell Biol, 2018, 19(12): 774-790. DOI: 10.1038/s41580-018-0074-2.
[10] DIENSTMANN R, VERMEULEN L, GUINNEY J, et al. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer[J]. Nat Rev Cancer, 2017, 17(2): 79-92. DOI: 10.1038/nrc.2016.126.
[11] OKUGAWA Y, GRADY W M, GOEL A. Epigenetic alterations in colorectal cancer: emerging biomarkers[J]. Gastroenterology, 2015, 149(5): 1204-1225. DOI: 10.1053/j.gastro.2015.07.011.
[12] GAYON J. From mendel to epigenetics: history of genetics[J]. C R Biol, 2016, 339(7/8): 225-230. DOI: 10.1016/j.crvi.2016.05.009.
[13] SUN B, HU L, LUO Z Y, et al. DNA methylation perspectives in the pathogenesis of autoimmune diseases[J]. Clin Immunol, 2016, 164: 21-27. DOI: 10.1016/j.clim.2016.01.011.
[14] GAUDET F, HODGSON J G, EDEN A, et al. Induction of tumors in mice by genomic hypomethylation[J]. Science, 2003, 300(5618): 489-492. DOI: 10.1126/science.1083558.
[15] DODGE J E, OKANO M, DICK F, et al. Inactivation of dnmt3b in mouse embryonic fibroblasts results in DNA hypomethylation, chromosomal instability, and spontaneous immortalization[J]. J Biol Chem, 2005, 280(18): 17986-17991. DOI: 10.1074/jbc.M413246200.
[16] TAHARA T, SHIBATA T, ARISAWA T, et al. CpG island promoter methylation(CIHM)status of tumor suppressor genes correlates with morphological appearances of gastric cancer[J]. Anticancer Res, 2010, 30(1): 239-244.
[17] WERNER R J, KELLY A D, ISSA J P J. Epigenetics and precision oncology[J]. Cancer J, 2017, 23(5): 262-269. DOI: 10.1097/PPO.0000000000000281.
[18] LIANG G N, WEISENBERGER D J. DNA methylation aberrancies as a guide for surveillance and treatment of human cancers[J]. Epigenetics, 2017, 12(6): 416-432. DOI: 10.1080/15592294.2017.1311434.
[19] MENG H, CAO Y, QIN J Z, et al. DNA methylation, its mediators and genome integrity[J]. Int J Biol Sci, 2015, 11(5): 604-617. DOI: 10.7150/ijbs.11218.
[20] LAWRENCE M, DAUJAT S, SCHNEIDER R. Lateral thinking: how histone modifications regulate gene expression[J]. Trends Genet, 2016, 32(1): 42-56. DOI: 10.1016/j.tig.2015.10.007.
[21] TALBERT P B, HENIKOFF S. Histone variants on the move: substrates for chromatin dynamics[J]. Nat Rev Mol Cell Biol, 2017, 18(2): 115-126. DOI: 10.1038/nrm.2016.148.
[22] TALBERT P B, HENIKOFF S. Histone variants—ancient wrap artists of the epigenome[J]. Nat Rev Mol Cell Biol, 2010, 11(4): 264-275. DOI: 10.1038/nrm2861.
[23] 李泰. G9A介导的Histone H3 lysine9甲基化作用在自噬调控中的分子基础[D]. 重庆:西南大学, 2014: 1-141.
[24] 王维, 孟智启, 石放雄. 组蛋白修饰及其生物学效应[J]. 遗传, 2012, 34(7): 20-28. DOI: 10.3724/SP.J.1005.2012.00810.
[25] SHI X F, SUN M, LIU H B, et al. Long non-coding RNAs: a new frontier in the study of human diseases[J]. Cancer Lett, 2013, 339(2): 159-166. DOI: 10.1016/j.canlet.2013.06.013.
[26] ESTELLER M. Non-coding RNAs in human disease[J]. Nat Rev Genet, 2011, 12(12): 861-874. DOI: 10.1038/nrg3074.
[27] ANASTASIADOU E, JACOB L S, SLACK F J. Non-coding RNA networks in cancer[J]. Nat Rev Cancer, 2018, 18(1): 5-18. DOI: 10.1038/nrc.2017.99.
[28] LI C H, CHEN Y C. Targeting long non-coding RNAs in cancers: progress and prospects[J]. Int J Biochem Cell Biol, 2013, 45(8): 1895-1910. DOI: 10.1016/j.biocel.2013.05.030.
[29] SCHMITT A M, CHANG H Y. Long noncoding RNAs in cancer pathways[J]. Cancer Cell, 2016, 29(4): 452-463. DOI: 10.1016/j.ccell.2016.03.010.
[30] RUAN X B. Long non-coding RNA central of glucose homeostasis[J]. J Cell Biochem, 2016, 117(5): 1061-1065. DOI: 10.1002/jcb.25427.
[31] LI H M, WANG L R, WU Y, et al. Very-low-dose decitabine is effective in treating intermediate-or high-risk myelodysplastic syndrome[J]. Acta Haematol, 2017, 138(3): 168-174. DOI: 10.1159/000479485.
[32] GORE L, TRICHE T J, FARRAR J E, et al. A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML[J]. Clin Epigenetics, 2017, 9(1): 108. DOI: 10.1186/s13148-017-0411-x.
[33] SEKERES M A, OTHUS M, LIST A F, et al. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117[J]. J Clin Oncol, 2017, 35(24): 2745-2753. DOI: 10.1200/JCO.2015.66.2510.
[34] SANTINI V, ALLIONE B, ZINI G, et al. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia[J]. Leukemia, 2018, 32(2): 413-418. DOI: 10.1038/leu.2017.186.
[35] 吴璇. 地西他滨联合顺铂对结直肠癌化疗增敏的研究[D]. 北京:中国人民解放军医学院, 2015: 1-47.
[36] 虞淦军. 地西他滨为基础的协同性免疫疗法治疗微卫星稳定性结直肠癌及机制研究[D]. 上海:中国人民解放军海军军医大学, 2018: 1-124.
[37] LI P K, GENG X P, ZHU L X. DNA methylation inhibitors: research advances[J]. J Int Pharm Res, 2010, 37(3): 198-202.
[38] 高曰文, 朱耀明, 王艳林, 等. 盐酸普鲁卡因对人结肠癌HT-29细胞Syk基因甲基化及表达的影响[J]. 生物技术通报, 2010(12): 173-177. DOI: 10.13560/j.cnki.biotech.bull.1985.2010.12.044.
[39] 梁田田, 李日恒, 张爱民, 等. 普鲁卡因对结肠癌细胞中孕酮及脂联素受体3甲基化的影响[J]. 中国现代医学杂志, 2020, 30(4): 16-20. DOI: 10.3969/j.issn.1005-8982.2020.04.003.
[40] 党晓东, 来炳祺, 何元. 普鲁卡因抑制脂多糖诱导的结肠癌细胞肿瘤侵袭性的作用机制[J]. 局解手术学杂志, 2018, 27(8): 541-544. DOI: 10.11659/jjssx.03E018023.
[41] SINGH B N, SHANKAR S, SRIVASTAVA R K. Green tea catechin, epigallocatechin-3-gallate(EGCG): mechanisms, perspectives and clinical applications[J]. Biochem Pharmacol, 2011, 82(12): 1807-1821. DOI: 10.1016/j.bcp.2011.07.093.
[42] THURN K T, THOMAS S, RAHA P, et al. Histone deacetylase regulation of ATM-mediated DNA damage signaling[J]. Mol Cancer Ther, 2013, 12(10): 2078-2087. DOI: 10.1158/1535-7163.mct-12-1242.
[43] MARIADASON J M. HDACs and HDAC inhibitors in colon cancer[J]. Epigenetics, 2008, 3(1): 28-37. DOI: 10.4161/epi.3.1.5736.
[44] 李青云, 肖鹏, 司徒伟基, 等. HDAC1对结直肠癌细胞凋亡及侵袭能力的影响[J]. 胃肠病学和肝病学杂志, 2018, 27(7): 781-785. DOI: 10.3969/j.issn.1006-5709.2018.07.015.
[45] THANGARAJU M, CARSWELL K N, PRASAD P D, et al. Colon cancer cells maintain low levels of pyruvate to avoid cell death caused by inhibition of HDAC1/HDAC3[J]. Biochem J, 2009, 417(1): 379-389. DOI: 10.1042/bj20081132.
[46] ZHANG H, DAI X F, QI Y, et al. Histone deacetylases inhibitors in the treatment of retinal degenerative diseases: overview and perspectives[J]. J Ophthalmol, 2015, 2015: 250812. DOI: 10.1155/2015/250812.
[47] SONNEMANN J, MARX C, BECKER S, et al. p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors[J]. Br J Cancer, 2014, 110(3): 656-667. DOI: 10.1038/bjc.2013.742.
[48] TUMBER A, COLLINS L S, PETERSEN K D, et al. The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo[J]. Cancer Chemother Pharmacol, 2007, 60(2): 275-283. DOI: 10.1007/s00280-006-0374-7.
[49] BULTMAN S J. Interplay between diet, gut microbiota, epigenetic events, and colorectal cancer[J]. Mol Nutr Food Res, 2017, 61(1): 1500902. DOI: 10.1002/mnfr.201500902.
[50] MANDL P, NAVARRO-COMPÁN V, TERSLEV L, et al. EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice[J]. Ann Rheum Dis, 2015, 74(7): 1327-1339. DOI: 10.1136/annrheumdis-2014-206971.
[51] 寇玉玲. SETDB1在结直肠癌增殖和凋亡中的作用研究[D]. 泸州:西南医科大学, 2017: 1-67.
[52] 陈克力. 甲基化转移酶SETDB1及cNOTCH1受体蛋白在结直肠癌中的功能及分子机制初步研究[D]. 广州:南方医科大学, 2017: 1-142.
[53] YU G J, WU Y F, WANG W Y, et al. Correction to: low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment[J]. Cell Mol Immunol, 2020, 17(1): 111-112. DOI: 10.1038/s41423-019-0340-z.